These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 37743261)
1. Use of molnupiravir: A Danish nationwide drug utilization study. Ladebo L; Rasmussen L; Jensen PB; Lindahl M; Øvrehus A; Hallas J; Reilev M Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5700. PubMed ID: 37743261 [TBL] [Abstract][Full Text] [Related]
2. Characteristics and Outcomes of US Veterans With Immunocompromised Conditions at High Risk of SARS-CoV-2 Infection With or Without Receipt of Oral Antiviral Agents. Gentry CA; Nguyen PN; Thind SK; Kurdgelashvili G; Williams RJ Clin Infect Dis; 2024 Feb; 78(2):330-337. PubMed ID: 37619991 [TBL] [Abstract][Full Text] [Related]
3. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007 [TBL] [Abstract][Full Text] [Related]
4. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. Jayk Bernal A; Gomes da Silva MM; Musungaie DB; Kovalchuk E; Gonzalez A; Delos Reyes V; Martín-Quirós A; Caraco Y; Williams-Diaz A; Brown ML; Du J; Pedley A; Assaid C; Strizki J; Grobler JA; Shamsuddin HH; Tipping R; Wan H; Paschke A; Butterton JR; Johnson MG; De Anda C; N Engl J Med; 2022 Feb; 386(6):509-520. PubMed ID: 34914868 [TBL] [Abstract][Full Text] [Related]
5. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong. Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790 [TBL] [Abstract][Full Text] [Related]
6. Molnupiravir and Its Antiviral Activity Against COVID-19. Tian L; Pang Z; Li M; Lou F; An X; Zhu S; Song L; Tong Y; Fan H; Fan J Front Immunol; 2022; 13():855496. PubMed ID: 35444647 [TBL] [Abstract][Full Text] [Related]
7. Effect of molnupiravir on SARS-CoV-2 evolution in immunocompromised patients: a retrospective observational study. Fountain-Jones NM; Vanhaeften R; Williamson J; Maskell J; Chua IJ; Charleston M; Cooley L Lancet Microbe; 2024 May; 5(5):e452-e458. PubMed ID: 38527471 [TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 Antiviral Prescribing Gaps Among Nonhospitalized High-Risk Adults. Levy ME; Burrows E; Chilunda V; Pawloski PA; Heaton PR; Grzymski J; Goldman JD; McEwen LM; Wyman D; Dei Rossi A; Dai H; Isaksson M; Washington NL; Basler T; Tsan K; Nguyen J; Ramirez J; Sandoval E; Lee W; Lu J; Luo S Clin Infect Dis; 2024 Jun; 78(6):1531-1535. PubMed ID: 38170452 [TBL] [Abstract][Full Text] [Related]
13. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Fischer WA; Eron JJ; Holman W; Cohen MS; Fang L; Szewczyk LJ; Sheahan TP; Baric R; Mollan KR; Wolfe CR; Duke ER; Azizad MM; Borroto-Esoda K; Wohl DA; Coombs RW; James Loftis A; Alabanza P; Lipansky F; Painter WP Sci Transl Med; 2022 Jan; 14(628):eabl7430. PubMed ID: 34941423 [TBL] [Abstract][Full Text] [Related]
14. Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trial. Png ME; Harris V; Grabey J; Hart ND; Jani BD; Butler D; Carson-Stevens A; Coates M; Cureton L; Dobson M; Dorward J; Evans P; Francis N; Gbinigie OA; Hayward G; Holmes J; Hood K; Khoo S; Ahmed H; Lown M; McKenna M; Mort S; Nguyen-Van-Tam JS; Rahman NM; Richards DB; Thomas NP; van Hecke O; Hobbs R; Little P; Yu LM; Butler CC; Petrou S; Br J Gen Pract; 2024 Aug; 74(745):e570-e579. PubMed ID: 38228357 [TBL] [Abstract][Full Text] [Related]
15. Antiviral Efficacy of Molnupiravir for COVID-19 Treatment. Bai Y; Shen M; Zhang L Viruses; 2022 Apr; 14(4):. PubMed ID: 35458493 [TBL] [Abstract][Full Text] [Related]
16. Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients. Standing JF; Buggiotti L; Guerra-Assuncao JA; Woodall M; Ellis S; Agyeman AA; Miller C; Okechukwu M; Kirkpatrick E; Jacobs AI; Williams CA; Roy S; Martin-Bernal LM; Williams R; Smith CM; Sanderson T; Ashford FB; Emmanuel B; Afzal ZM; Shields A; Richter AG; Dorward J; Gbinigie O; Van Hecke O; Lown M; Francis N; Jani B; Richards DB; Rahman NM; Yu LM; Thomas NPB; Hart ND; Evans P; Andersson M; Hayward G; Hood K; Nguyen-Van-Tam JS; Little P; Hobbs FDR; Khoo S; Butler C; Lowe DM; Breuer J; Nat Commun; 2024 Feb; 15(1):1652. PubMed ID: 38396069 [TBL] [Abstract][Full Text] [Related]